文献速递心力衰竭与心肌病

非奈利酮对HFmrEF/HFpEF患者KCCQ的影响:FINEARTS-HF预设分析

Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF.
PubMed 文献 · J Am Coll Cardiol · 2024-09-29

FINEARTS-HF预设分析纳入5986例HFmrEF/HFpEF患者,按基线KCCQ-TSS三分位分层,评估非奈利酮对主要终点及KCCQ-TSS的影响。结果显示非奈利酮在各KCCQ-TSS三分位均降低主要终点风险(交互P=0.89),12个月时KCCQ-TSS平均改善1.62分(95%CI 0.69-2.56,P<0.001)。

要点

  • 非奈利酮在各基线KCCQ-TSS三分位均降低心血管死亡和心衰恶化事件风险。
  • 非奈利酮12个月时KCCQ-TSS较安慰剂平均改善1.62分(95%CI 0.69-2.56,P<0.001)。
  • 基线KCCQ-TSS越低,主要终点风险越高,但非奈利酮疗效不受基线症状负担影响。

核心结论

  • 在HFmrEF/HFpEF患者中,非奈利酮显著减少心衰事件并改善健康状态,且获益跨越基线KCCQ-TSS谱。

研究设计与样本

  • FINEARTS-HF预设分析纳入6001例HFmrEF/HFpEF患者,其中5986例(99.8%)有基线KCCQ-TSS记录。
  • 患者按基线KCCQ-TSS三分位分层,评估非奈利酮对比安慰剂对主要终点及KCCQ-TSS变化的影响。

主要发现

  • 基线KCCQ-TSS越低(越差),主要终点风险越高。
  • 非奈利酮对比安慰剂的主要终点风险比:三分位1(0-<57分)RR 0.82(95%CI 0.68-1.00);三分位2(57-<81分)RR 0.88(95%CI 0.70-1.11);三分位3(81-100分)RR 0.88(95%CI 0.69-1.14),交互P=0.89。
  • 12个月时非奈利酮较安慰剂显著改善KCCQ-TSS,平均差异1.62分(95%CI 0.69-2.56,P<0.001)。
  • 非奈利酮组临床意义恶化的患者数量数值上更少,KCCQ-TSS改善的患者更多。

关键数值与推荐

  • KCCQ-TSS三分位界值:三分位1为0-<57分,三分位2为57-<81分,三分位3为81-100分。
  • 基线KCCQ-TSS中位数为69.8分(满分100,分数越高健康状态越好)。

临床怎么用

  • 对于HFmrEF/HFpEF患者,无论基线症状负担轻重,均可考虑使用非奈利酮以降低心衰事件风险并改善健康状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with heart failure (HF) are limited by symptoms and have impaired quality of life. The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a patient-reported outcome measure that enables evaluation of the effect of HF and the impact of new therapies on health status in patients with HF. OBJECTIVES: This prespecified analysis of FINEARTS-HF (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure) assessed the efficacy and safety of finerenone according to baseline KCCQ Total Symptom Score (TSS) and the effect of finerenone on KCCQ-TSS. METHODS: FINEARTS-HF tested the efficacy of the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone, compared with placebo, in patients with HF with mildly reduced ejection fraction/preserved ejection fraction. The primary endpoint was the composite of cardiovascular death and total worsening HF events. The KCCQ was completed by patients at randomization and at 6, 9, and 12 months after randomization. Change in KCCQ-TSS was a key secondary endpoint. Patients were stratified by KCCQ-TSS tertiles at baseline. The association between KCCQ tertile and clinical outcomes was evaluated using semiparametric proportional-rates models for total events and Cox models for time-to-first-event data, and the effects of finerenone vs placebo on the primary endpoint were assessed across tertiles of KCCQ-TSS. RESULTS: Of the 6,001 participants in FINEARTS-HF, 5,986 (99.8%) had baseline KCCQ-TSS recorded (median score 69.8 of a possible 100; higher score = better health status). Lower (worse) KCCQ-TSS was associated with a higher risk of the primary endpoint. Finerenone, compared with placebo, reduced the risk of the primary endpoint across the range of KCCQ-TSS: tertile 1 (score 0-<57): RR: 0.82 (95% CI: 0.68-1.00); tertile 2 (57-<81): 0.88 (95% CI: 0.70-1.11); tertile 3 (81-100): 0.88 (95% CI: 0.69-1.14) (Pinteraction = 0.89). Compared with placebo, finerenone significantly improved KCCQ-TSS from baseline with a mean difference at 12 months of 1.62 points (95% CI: 0.69-2.56 points) (P < 0.001). Numerically fewer finerenone-treated patients experienced clinically meaningful deterioration, and more had improvements in KCCQ-TSS. CONCLUSIONS: Finerenone significantly reduced HF events and improved health status in patients with HF and mildly reduced ejection fraction/preserved ejection fraction across the spectrum of KCCQ-TSS at baseline. (Study to Evaluate the Efficacy [Effect on Disease] and Safety of Finerenone on Morbidity [Events Indicating Disease Worsening] & Mortality [Death Rate] in Participants With Heart Failure and Left Ventricular Ejection Fraction [Proportion of Blood Expelled Per Heart Stroke] Greater or Equal to 40% [FINEARTS-HF], NCT04435626; Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure; EudraCT 2020-000306-29).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Yang M, Henderson AD, Talebi A, et al. Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF. J Am Coll Cardiol. 2024. PMID: 39520455. doi:10.1016/j.jacc.2024.09.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。